Entourage wins. Dr. Nils Sunder-Plassmann. As Head of Pharma.

Management consultancy Entourage is proud to welcome Dr. Nils Sunder-Plassmann to the team as Head of Pharma.

Entourage, a management consultancy based in Munich, Basel, Milan and Boston, is strengthening its pharma team with Dr. Nils Sunder-Plassmann, who will take on the role of Head of Pharma.

Nils Sunder-Plassmann, who holds a doctorate in pharmaceuticals, has extensive experience in regulatory affairs, clinical development and project management. He studied chemistry at the universities of Karlsruhe and Manchester. In Leipzig, he completed his doctorate at the Institute of Organic Chemistry on novel active substances in cancer therapy. Parallel to his doctorate, he completed a postgraduate course in toxicology. His core competencies include international drug approvals, project management, especially of clinical development programs and regulatory affairs projects as well as structure and process optimization. During his professional career, he has held various management positions at well-known companies.

Testimonials.

Dr. Sunder-Plassmann is looking forward to the new challenge at Entourage: "I am looking forward to incorporating my 20 years of experience in pharmaceutical research and consulting into Entourage's unique business model. The impressive response from the pharmaceutical industry to Entourage's diverse and flexible service offerings makes me extremely confident about the future of the pharma department."
Moritz Haucke, Managing Partner and founder of Entourage, is also positive about the new head of the pharma division: "With Dr. Nils Sunder-Plassmann, we are gaining an experienced project manager in the pharma sector. We are confident that he will make a valuable contribution to our growth."

Brief profile of Dr. Nils Sunder-Plassmann.

Dr. Nils Sunder-Plassmann studied chemistry at the University of Manchester Institute of Science and Technology (UMIST) and the Karlsruhe Institute of Technology (KIT). At the University of Leipzig, he completed his doctorate in natural sciences at the Institute of Organic Chemistry on angiogenesis inhibitors as active agents in oncology. He also completed a postgraduate course at the Faculty of Medicine to qualify as a "Specialist Chemist in Toxicology".
During his more than 20-year career, Dr. Sunder-Plassmann has held various roles and management positions in consulting for the pharmaceutical industry and research and development. He has extensive experience in regulatory affairs, clinical development and project management. His core competencies include international drug approvals, process and risk management.
Dr. Nils Sunder-Plassmann supports Entourage as Head of Pharma.

Short Profile Entourage.

Entourage is a life sciences consultancy headquartered in Munich with additional offices in Basel, Milan and Boston. The company has a multidisciplinary team of over 180 industry-experienced consultants who work closely with market leaders in the pharmaceutical and medical device industries to develop customized solutions. Through its unique hybrid approach, combining project and management consulting, Entourage is able to offer its clients customized solutions in the life sciences sector.

Entourage is looking for life science professionals.

Become part of the team now.

Share Article.

Facebook
Twitter
LinkedIn
XING
WhatsApp
Email

Newsletter.

Read more.

Entourage goes. CPhI 2025. In Frankfurt.
From October 28 - 30, 2025, the international ...
Entourage wins. Volker Bargon. As a member of the advisory board.
Volker Bargon will become a member of the ...
Entourage wins. Dr Markus Boehringer. As medical technology advisor.
Dr Markus Boehringer becomes Entourage advisory board member in the field of medical technology.
Entourage becomes a member. of the MedTec Cluster. Medical Valley Hechingen.
Entourage becomes a member of the medical technology cluster Medical Valley Hechingen.
Entourage wins. Dr. Christina Ziegenberg. As a Member of the Advisory Board.
Dr. Christina Ziegenberg will be a member of the Advisory Board from November 1, 2023.